Cardiovascular

Ian Riddock, MD, and Leandro N. Slipczuk, MD, PhD, discuss the importance of LDL-C management as part of the discharge plan for patients, as well as ensuring continuity of care from the inpatient to outpatient setting.

Dr Brinton highlights the importance of adjunct therapies in LDL management.

Dr Riddock explains how the ASCVD treatment landscape lends itself to initiation of therapy beyond statins in the inpatient setting.

Eliot Brinton, MD, provides a warning concerning “maximally-tolerated statin dosing” and provides general guidance for optimal dosing.

Ian Riddock, MD, describes the high-risk patient with ASCVD that is appropriate for early intensive lipid lowering.

Ian Riddock, MD, describes residual cardiovascular risk, both with and without the use of statin therapies.

An expert advises how to optimize the care continuum for patients with ASCVD.

Dr Ian Riddock explains the patient journey post-myocardial infarction (MI), from hospital to outpatient care.

Ian Riddock, MD, discusses the burden of atherosclerotic cardiovascular disease (ASCVD) and multi-societal guideline recommendations for lipid management.

People with high risk of obstructive sleep apnea presented with significant changes in key arteries indicative of accelerated vascular aging, a known contributor to cardiovascular disease (CVD).

Low-density lipoprotein cholesterol (LDL-C)–lowering therapies have yielded significant value to society through reduced costs for both fatal and nonfatal cardiovascular disease events. The vast majority of this value has accrued to patients.

Patients with chronic cardiac conditions benefited from a health care program that strengthened collaboration between general practitioners and cardiology specialists in Baden-Wuerttemberg, Germany.

Premature coronary artery disease (CAD) is an aggressive disease with a high rate of ischemic recurrences and premature death, researchers said.

The top 5 most-read conference stories of 2020 on AJMC.com included stories about study results on the impact that new therapies are having on cardiovascular and renal health.

A recent study sought to estimate the incidence of clinical events such as bleeding, myocardial infarction, and all-cause mortality in patients with acute myocardial infarction and chronic coronary syndrome who received dual antiplatelet therapy (DAPT) after coronary stenting.

The distinction between valvular and nonvalvular atrial fibrillation (AF) has been a persistent point of confusion for clinicians.

The American College of Cardiology provides new guidance on the best therapy to prevent blood clots for patients with atherosclerotic cardiovascular disease who also have atrial fibrillation or venous thromboembolism and require an anticoagulant.

Giving patients icosapent ethyl, or Vascepa, led to a 52% reduction of the total patient-reported symptom outcome prevalence score as compared with a 24% decline for outpatients who received usual care.

There was a significant decrease in the rates of cardiovascular complications and mortality in adults with diabetes in South Korea, but other conditions increased.

Despite heavy alcohol consumption being linked to increased incidence of atrial fibrillation (AF) and bleeding in patients with the condition, recommendations to control heavy drinking among this patient population are lacking.

Childhood abuse, household dysfunction, and neglect were linked in a recent study to an increased risk of developing cardiovascular disease in adulthood.

A recent prospective, observational study investigated the use of direct oral anticoagulants for use in patients with postoperative atrial fibrillation and found favorable safety and efficacy results.

The use of a population health management tool may reduce adverse events that may arise from the inappropriate prescribing of direct-acting oral anticoagulants (DOACs).

It remains unclear whether measures of magnetic resonance imaging plaque characteristics are associated with cardiovascular disease events independent of plaque burden at the population level.